Management of Persistent Pulmonary Hypertension After Correction of Congenital Heart Defect with Autologous Marrow-Derived Mononuclear Stem Cell Injection into the Pulmonary Artery: A Pilot Study

Amoozgar, Hamid; Banafi, Pegah; Mohammadi, Hamid; Edraki, Mohammad Reza; Mehdizadegan, Nima; Ajami, Gholamhossein; Borzouee, Mohammad; Keshaarz, Kambiz; Moradi, Poria; Dehghani, Elham

doi:10.1007/s00246-019-02273-2

Cited by 2 publications

(1 citation statement)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Congenital heart disease (CHD) is a common cardiovascular disease in pediatrics with a complex etiology associated with multiple factors. If CHD is not treated in a timely manner, the decrease in cardiac output, the increase in cardiac load, and the increase in pulmonary blood flow lead to an increase in mean pulmonary arterial pressure (MPAP), resulting in pulmonary arterial hypertension (PAH) and the loss of surgical opportunities in advanced irreversible PAH [ 1 , 2 ]. Therefore, it’s critical to get a diagnosis and treatment as soon as possible in order to lower mortality rate and enhance quality of life for PAH-CHD patients.…”

Section: Introductionmentioning

confidence: 99%

Identification of potential serum biomarkers for congenital heart disease children with pulmonary arterial hypertension by metabonomics

Jin

et al. 2023

BMC Cardiovasc Disord

View full text Add to dashboard Cite

Background Pulmonary arterial hypertension is a common complication in patients with congenital heart disease. In the absence of early diagnosis and treatment, pediatric patients with PAH has a poor survival rate. Here, we explore serum biomarkers for distinguishing children with pulmonary arterial hypertension associated with congenital heart disease (PAH-CHD) from CHD. Methods Samples were analyzed by nuclear magnetic resonance spectroscopy-based metabolomics and 22 metabolites were further quantified by ultra-high-performance liquid chromatography–tandem mass spectroscopy. Results Serum levels of betaine, choline, S-Adenosyl methionine (SAM), acetylcholine, xanthosine, guanosine, inosine and guanine were significantly altered between CHD and PAH-CHD. Logistic regression analysis showed that combination of serum SAM, guanine and N-terminal pro-brain natriuretic peptide (NT-proBNP), yielded the predictive accuracy of 157 cases was 92.70% with area under the curve of the receiver operating characteristic curve value of 0.9455. Conclusion We demonstrated that a panel of serum SAM, guanine and NT-proBNP is potential serum biomarkers for screening PAH-CHD from CHD.

show abstract

Section: Introductionmentioning

confidence: 99%

Identification of potential serum biomarkers for congenital heart disease children with pulmonary arterial hypertension by metabonomics

Jin

et al. 2023

BMC Cardiovasc Disord

View full text Add to dashboard Cite

show abstract

Pediatric Pulmonary Hypertension: Definitions, Mechanisms, Diagnosis, and Treatment

Mukherjee

Konduri

2021

Comprehensive Physiology

View full text Add to dashboard Cite

Pediatric pulmonary hypertension (PPH) is a multifactorial disease with diverse etiologies and presenting features. Pulmonary hypertension (PH), defined as elevated pulmonary artery pressure, is the presenting feature for several pulmonary vascular diseases. It is often a hidden component of other lung diseases, such as cystic fibrosis and bronchopulmonary dysplasia. Alterations in lung development and genetic conditions are an important contributor to pediatric pulmonary hypertensive disease, which is a distinct entity from adult PH. Many of the causes of pediatric PH have prenatal onset with altered lung development due to maternal and fetal conditions. Since lung growth is altered in several conditions that lead to PPH, therapy for PPH includes both pulmonary vasodilators and strategies to restore lung growth. These strategies include optimal alveolar recruitment, maintaining physiologic blood gas tension, nutritional support, and addressing contributing factors, such as airway disease and gastroesophageal reflux. The outcome for infants and children with PH is highly variable and largely dependent on the underlying cause. The best outcomes are for neonates with persistent pulmonary hypertension (PPHN) and reversible lung diseases, while some genetic conditions such as alveolar capillary dysplasia are lethal.

show abstract

Management of Persistent Pulmonary Hypertension After Correction of Congenital Heart Defect with Autologous Marrow-Derived Mononuclear Stem Cell Injection into the Pulmonary Artery: A Pilot Study

Cited by 2 publications

References 26 publications

Identification of potential serum biomarkers for congenital heart disease children with pulmonary arterial hypertension by metabonomics

Identification of potential serum biomarkers for congenital heart disease children with pulmonary arterial hypertension by metabonomics

Pediatric Pulmonary Hypertension: Definitions, Mechanisms, Diagnosis, and Treatment

Contact Info

Product

Resources

About